Research - Orexigen Therapeutics (OREX) is trading at $6.00 this afternoon, one week ahead of the September 11 FDA approval decision for Contrave (NB32). We suggested buying OREX in late July at $5.20 as … Continue Reading
Premium: Read NowResearch - For long-term PropThink subscribers, few investments have yielded higher profits than Illumina (ILMN). Since our initiation of coverage in November 2012, shares of the San Diego-based company … Continue Reading
Premium: Read NowResearch - A risk-mitigating strategy for being involved in Alcobra’s (ADHD) upcoming phase 3 results in ADHD.
Premium: Read NowResearch - OWN PCYC as Imbruvica continues to secure foothold in oncology. Cash and emerging pipeline offer options diversification for this small company. Second quarter results demonstrate continued growth … Continue Reading
Premium: Read NowResearch - Takeaways from OncoGeneX's (OGXI). Knowing this could make or save you some $$.
Premium: Read NowResearch - Amicus Therapeutics (FOLD), with a current market value of just $271 million, represents a high-risk, high reward play for investors willing to bet that the … Continue Reading
Premium: Read NowResearch - OGXI is a speculative, micro-cap oncology company – now, essentially a call option with multiple shots on goal. $60 million in cash/equivalents provide a backdrop … Continue Reading
Premium: Read Now
